Navigation Links
Eurand Announces Positive Phase III Clinical Study Results

Company's Pancreatic Enzyme Replacement Therapy Significantly Improved Absorption of Fat and Protein during Clinical Trials

MILAN, Italy and DAYTON, Ohio, April 04, 2007 /PRNewswire/ -- Eurand, a global specialty pharmaceutical company, today unveiled data from two phase III clinical trials on its lead product candidate, Zentase(TM), formerly EUR-1008, for the treatment of Exocrine Pancreatic Insufficiency (EPI). The US Food and Drug Administration (FDA) granted fast track status for Zentase for the treatment of EPI. The company intends to file for FDA approval during the second quarter of 2007 for this potentially first-in-class pancreatic enzyme replacement therapy.

Zentase is a zero-overfill, highly-stable, porcine-derived pancreatic enzyme replacement therapy used to treat EPI and was designed to meet FDA guidelines for pancreatic enzyme replacement products(1). According to the FDA, no currently marketed pancreatic enzyme product (PEP) has been shown to demonstrate consistent enzyme bioactivity that results in predictable safety and effectiveness(2). Many of the current enzyme products contain overfill to compensate for product instability during shelf life, which can lead to variability in dosing. As a highly-stable product, Zentase does not require overfill. Currently, there are no FDA approved PEPs for the treatment of EPI on the market in the US.

"We are excited to present the results of our phase III studies supporting Zentase for the full spectrum of cystic fibrosis patients suffering from EPI, including those needing limited supplementation to those with very aggressive enzyme deficiency," said Gearoid Faherty, Eurand Chairman and CEO.

Zentase met all primary and secondary endpoints in two phase III clinical trials. The studies were designed to determine whether the product candidate could alleviate serious malabsorption associated with EPI in both a pediatric (younger than 7 ye
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
2. Eurand to Present Zentase Phase III Data
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Eurand Announces Positive Phase III Clinical Study Results
(Date:2/27/2015)... KING OF PRUSSIA, Pa. , Feb. 27, 2015 ... part of its ongoing commitment to the global bleeding ... it is donating 2 million international units (IUs) of ... WFH is an international not-for- profit organization which has ... and other inherited bleeding disorders. The donation supports the ...
(Date:2/27/2015)... 27, 2015 ... für kongestive Herzinsuffizienz (CHF) in seiner ersten ...     Die israelische ... Herzüberwachungssystem für Patienten mit kongestiver Herzinsuffizienz (CHF) ... ein Finanzierungsvorhaben über 5 Mio. USD abgeschlossen ...
(Date:2/27/2015)... 2015  Two mass spectrometry technologies MALDI ... their effectiveness is established, according to biotechnology ... says that while mass spectrometry (mass spec ... in proteomic biomarker discovery and validation, mass ... techniques has struggled to elucidate molecular distribution ...
Breaking Medicine Technology:CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today ... present a company update at the Baird Health Care Conference ... a.m. ET.   Interested parties may access a ... section of the BioMarin website, www.BMRN.com .  A replay ...
... 30, 2011 Perrigo Company (Nasdaq: PRGO ... approval from the U.S. Food and Drug Administration for ... the generic version of Extina® Ketoconazole Foam, 2%. Perrigo ... to file, enabling 180 days of marketing exclusivity. This ...
Cached Medicine Technology:BioMarin to Present at the Baird Health Care Conference 2Perrigo Announces FDA Final Approval for Ketoconazole Foam, 2% 2
(Date:2/28/2015)... Kaylie Corrigan, Outdoor Supervisor at Back2Basics Outdoor ... student obtaining her Masters degree in social work at ... psychoeducation on substance use for teens at the local ... her studies. , “Even though these students are young, ... the high school and junior high school level,” said ...
(Date:2/28/2015)... ON (PRWEB) February 28, 2015 The ... to announce that they have officially relaunched their website. ... more user-friendly, but it contains a new section about ... access to read the full biographies of each Friedman ... portion of the website was designed to provide our ...
(Date:2/28/2015)... 2015 Javon Bea Mercy Health ... Hospital as stroke capable by the State of Illinois, ... to Mercy Harvard Hospital. , The hospital was required ... ability to treat stroke according to national standards of ... stroke patients to bypass hospitals not designated as an ...
(Date:2/28/2015)... Memphis, TN: MedixSafe has retracted a previous ... security reader named Guardian 2. The correct product ... biometric scanner that significantly increases the complexity of ... biometric scanner provides fast and easy access for ... narcotics lockers with Vanguard technology tracks inventory ...
(Date:2/28/2015)... February 28, 2015 1Heart Caregiver ... showcased emerging brand at Houston Texas Franchise Expo ... Vegas sending its executive delegates headed by Vice-President ... Development and Training Randolph Clarito. , Franchise Expo ... held last February 4-7 and featured Franchise brands ...
Breaking Medicine News(10 mins):Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 3
... from your very early childhood i.e. before the age of ... ,Science has always pondered over 'infant amnesia' -inability ... being unable to form memories. , Yet researchers from ... for Advancement of Science, say that on the contrary, babies ...
... to commercial companies over clinical and preclinical trial data—could ... and harm public health, says Karin Timmermans of the ... Medicine. ,Writing in a personal capacity, Ms ... produce generic versions of the "flu drug" oseltamivir in ...
... 26 land beneficiaries in the capital comply with the lease ... a report submitted by the government to the Delhi High ... & Development Organization (L&DO) of the Delhi government had allotted ... out of which only 26 are currently operational. While DDA ...
... Beijing: China is to allow a pioneering doctor, currently under ... States to accept an award for her work on behalf// ... official told me I had permission to travel," retired professor ... where police have been holding her under house arrest for ...
... at the last straw to save their child; using Viagra to ... August when his mother was just into 24 weeks of pregnancy. ... but this was worsened when his lungs collapsed the day after ... had not closed properly. He was operated upon at 3 weeks ...
... promise in slowing progression and prolonging survival time in ... of targeted anti-cancer drugs that blocks the human epidermal ... the lives of patients with recurrent prostate cancer, a ... compound called pertuzumab, works by binding to and inhibiting ...
Cached Medicine News:Health News:Drug Companies Should Not Have a Monopoly Over Clinical Trial Data 2Health News:Private Hospitals Ignore Deal to Provide Free Treatment 2Health News:Viagra Plays Another Role-Premature Baby Saved 2Health News:New Drug Promises Prolonged Survival in Prostate Cancer Patients 2Health News:New Drug Promises Prolonged Survival in Prostate Cancer Patients 3
0.3 mm hook angled 45 degrees, 9 mm from tip to bend. Flat smooth handle with polished finish. Overall length: 4.6 inches....
2.0 mm cup. Angled 45 degree shaft 8 mm from tip to bend with flat handle and polished finish. Overall length: 4.8 inches....
Round, knurled handle with polished finish and straight shaft. 1 mm ring curette 1.5 mm high, 33 mm shaft. Overall length: 5.1 inches....
0.5 mm curette cup, reverse side of sandblasted to polish capsule. Round knurled handle with polished finish. Overall length: 5 inches....
Medicine Products: